Aurinia doses first subject in Phase Ia trial of AUR200 for autoimmune diseases
Aurinia Pharmaceuticals has initiated a Phase Ia single ascending dose clinical trial of AUR200, targeting autoimmune diseases. The trial aims to assess safety, tolerability, pharmacokinetics, and biomarker changes in healthy volunteers, with results expected in H1 next year. AUR200, an IgG4 Fc-fusion protein, inhibits B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), crucial for B-cell regulation. The company plans to develop AUR200 for disease states with limited market options, funded by available cash flow.
Reference News
Aurinia Pharmaceuticals has initiated a Phase Ia single ascending dose clinical trial of AUR200, targeting autoimmune diseases. The trial aims to assess safety, tolerability, pharmacokinetics, and biomarker changes in healthy volunteers, with results expected in H1 next year. AUR200, an IgG4 Fc-fusion protein, inhibits B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), crucial for B-cell regulation. The company plans to develop AUR200 for disease states with limited market options, funded by available cash flow.